• Kyodo

  • SHARE

Kyoto University researchers are set to begin the world’s first clinical trial of a drug identified using iPS cells to treat a rare bone disease, the university said Tuesday.

A team led by Junya Toguchida, a professor at the university, used induced pluripotent stem cells to develop a potential drug for fibrodysplasia ossificans progressiva (FOP), a rare disorder in which muscle tissue is gradually replaced by bone, inhibiting body movement.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)